14. Preclinical Pharmacology of DLX-001, a Novel Non-Hallucinogenic Neuroplastogen With the Potential for Treating Neuropsychiatric Diseases

Ketamine and psychedelic agents have shown efficacy for treating multiple neuropsychiatric disorders. Unfortunately, the dissociative experiences, hallucinations, and/or cardiotoxic properties of these compounds will limit their widespread clinical use. We designed a novel isotryptamine, DLX-001, to have similar efficacy as psychedelics and ketamine without producing untoward effects.